Antidepressant Use and Risk for Preeclampsia

Overview

Journal Epidemiology

Specialty Public Health

Date 2013 Jul 23

PMID 23873072

Citations 33

Authors

Kristin Palmsten

Krista F Huybrechts

Karin B Michels

Paige L Williams

Helen Mogun

Soko Setoguchi

Sonia Hernandez-Diaz

Affiliations

Soon will be listed here.

Abstract

Background: Prior studies suggest that women who use antidepressants during pregnancy have an increased risk for preeclampsia, yet the comparative safety of specific antidepressants remains unclear. US nationwide Medicaid Analytic eXtract (MAX) data have not been used to study medication safety during pregnancy.

Methods: We identified 100,942 pregnant women with depression from 2000 to 2007 MAX data. We used pharmacy dispensing records to ascertain exposure to selective serotonin reuptake inhibitor (SSRI), serotonin-norepenephrine reuptake inhibitor (SNRI), tricyclic, bupropion, other antidepressant monotherapy or polytherapy, and specific antidepressants, during the second trimester and first half of the third trimester. Relative risks (RRs) and 95% confidence intervals (CIs) were adjusted for delivery year, preeclampsia risk factors, depression severity proxies, other antidepressant indications, other medications, and healthcare utilization.

Results: The risk of preeclampsia was 5.4% among women with depression and no antidepressant exposure. Compared with these women, the risk for preeclampsia was higher among those receiving SNRI (RR: 1.52, 95% CI = 1.26-1.83) and tricyclic monotherapy (RR: 1.62, 95% CI = 1.23-2.12), but not SSRI monotherapy (RR: 1.00, 95% CI = 0.93-1.07) or other antidepressants. Compared with women receiving SSRI monotherapy, preeclampsia risk was higher among women with SNRI (RR: 1.54, 95% CI = 1.28-1.86) and tricyclic (RR: 1.64, 95% CI = 1.25-2.16) monotherapy. None of the specific SSRIs was associated with preeclampsia. The RR with venlafaxine was 1.57 (95% CI = 1.29-1.91) and with amitriptyline 1.72 (95% CI = 1.24-2.40).

Conclusions: In this population, SNRIs and tricyclics were associated with a higher risk of preeclampsia than SSRIs.

Citing Articles

Mirtazapine in pregnancy and lactation: A systematic review of adverse outcomes.

Ostenfeld A, Lyngholm S, Christensen S, Petersen T, Traerup Andersen J, Westergaard H Acta Psychiatr Scand. 2024; 151(1):6-32.

PMID: 39215625 PMC: 11608810. DOI: 10.1111/acps.13749.

Effect of Bright Light Therapy on Perinatal Depression: A Systematic Review and Meta-Analysis: Effet de la luminothérapie sur la dépression périnatale: une revue systématique et une méta-analyse.

Chen Y, Zhao J, Wang J, Peng L, Cai Z, Zou Z Can J Psychiatry. 2024; 69(10):737-748.

PMID: 38863243 PMC: 11485670. DOI: 10.1177/07067437241248051.

Case report: Olanzapine-associated water retention, high blood pressure, and subsequent preterm preeclampsia.

Izsak J, Falari D, Arnbert P, Pouragheli D, Kindblom J, Lasaitiene D Front Psychiatry. 2023; 14:1301348.

PMID: 38053540 PMC: 10694189. DOI: 10.3389/fpsyt.2023.1301348.

Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders.

Eleftheriou G, Zandonella Callegher R, Butera R, De Santis M, Cavaliere A, Vecchio S Int J Environ Res Public Health. 2023; 20(16).

PMID: 37623151 PMC: 10454549. DOI: 10.3390/ijerph20166565.

Mental Health Within 24 Months After Delivery Among Women with Common Pregnancy Conditions.

Ahrens K, Palmsten K, Lipkind H, Pfeiffer M, Gelsinger C, Ackerman-Banks C J Womens Health (Larchmt). 2023; 32(7):787-800.

PMID: 37192449 PMC: 10354313. DOI: 10.1089/jwh.2022.0367.

References

Rurak D, Lim K, Sanders A, Brain U, Riggs W, Oberlander T . Third trimester fetal heart rate and Doppler middle cerebral artery blood flow velocity characteristics during prenatal selective serotonin reuptake inhibitor exposure. Pediatr Res. 2011; 70(1):96-101. DOI: 10.1203/PDR.0b013e31821ba11a. View

Andersen J, Kristensen A, Bang-Andersen B, Stromgaard K . Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem Commun (Camb). 2009; (25):3677-92. DOI: 10.1039/b903035m. View

Schneeweiss S, Seeger J, Maclure M, Wang P, Avorn J, Glynn R . Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001; 154(9):854-64. DOI: 10.1093/aje/154.9.854. View

Smitherman T, Walters A, Maizels M, Penzien D . The use of antidepressants for headache prophylaxis. CNS Neurosci Ther. 2011; 17(5):462-9. PMC: 6493799. DOI: 10.1111/j.1755-5949.2010.00170.x. View

Rassen J, Glynn R, Brookhart M, Schneeweiss S . Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011; 173(12):1404-13. PMC: 3145392. DOI: 10.1093/aje/kwr001. View

Qiu C, Williams M, Calderon-Margalit R, Cripe S, Sorensen T . Preeclampsia risk in relation to maternal mood and anxiety disorders diagnosed before or during early pregnancy. Am J Hypertens. 2009; 22(4):397-402. DOI: 10.1038/ajh.2008.366. View

Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, Kieler H . Drug use during pregnancy in Sweden - assessed by the Prescribed Drug Register and the Medical Birth Register. Clin Epidemiol. 2011; 3:43-50. PMC: 3046184. DOI: 10.2147/CLEP.S16305. View

Bjoro K . In vitro perfusion studies on human umbilical arteries. I. Vasoactive effects of serotonin, PGF2 alpha and PGE2. Acta Obstet Gynecol Scand. 1986; 65(4):351-5. DOI: 10.3109/00016348609157359. View

Reis M, Kallen B . Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010; 40(10):1723-33. DOI: 10.1017/S0033291709992194. View

10.

De Vera M, Berard A . Antidepressant use during pregnancy and the risk of pregnancy-induced hypertension. Br J Clin Pharmacol. 2012; 74(2):362-9. PMC: 3630756. DOI: 10.1111/j.1365-2125.2012.04196.x. View

11.

Knol M, VanderWeele T . Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol. 2012; 41(2):514-20. PMC: 3324457. DOI: 10.1093/ije/dyr218. View

12.

Huybrechts K, Palmsten K, Mogun H, Kowal M, Avorn J, Setoguchi-Iwata S . National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry. 2013; 35(3):265-71. PMC: 4077674. DOI: 10.1016/j.genhosppsych.2012.12.010. View

13.

Patten S, Esposito E, Carter B . Reasons for antidepressant prescriptions in Canada. Pharmacoepidemiol Drug Saf. 2007; 16(7):746-52. DOI: 10.1002/pds.1385. View

14.

Sanchez S, Qiu C, Williams M, Lam N, Sorensen T . Headaches and migraines are associated with an increased risk of preeclampsia in Peruvian women. Am J Hypertens. 2008; 21(3):360-4. DOI: 10.1038/ajh.2007.46. View

15.

Yousif M, Chandrasekhar B, Kadavil E, Oriowo M . Noradrenaline-induced vasoconstriction in the uterine vascular bed of pregnant rats chronically treated with L-NAME: role of prostanoids. J Cardiovasc Pharmacol. 2003; 42(3):428-35. DOI: 10.1097/00005344-200309000-00015. View

16.

Ananth C, Vintzileos A . Medically indicated preterm birth: recognizing the importance of the problem. Clin Perinatol. 2008; 35(1):53-67, viii. DOI: 10.1016/j.clp.2007.11.001. View

17.

Bodnar L, Ness R, Markovic N, Roberts J . The risk of preeclampsia rises with increasing prepregnancy body mass index. Ann Epidemiol. 2005; 15(7):475-82. DOI: 10.1016/j.annepidem.2004.12.008. View

18.

Thase M, Tran P, Wiltse C, Pangallo B, Mallinckrodt C, Detke M . Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005; 25(2):132-40. DOI: 10.1097/01.jcp.0000155815.44338.95. View

19.

Schneeweiss S . Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006; 15(5):291-303. DOI: 10.1002/pds.1200. View

20.

Qiu C, Sanchez S, Lam N, Garcia P, Williams M . Associations of depression and depressive symptoms with preeclampsia: results from a Peruvian case-control study. BMC Womens Health. 2007; 7:15. PMC: 2148036. DOI: 10.1186/1472-6874-7-15. View